Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,674,579
  • Shares Outstanding, K 135,880
  • Annual Sales, $ 829,450 K
  • Annual Income, $ -1,630 K
  • EBIT $ 98 M
  • EBITDA $ 116 M
  • 60-Month Beta 1.21
  • Price/Sales 10.85
  • Price/Cash Flow 554.86
  • Price/Book 18.19

Options Overview Details

View History
  • Implied Volatility 61.05% (+2.50%)
  • Historical Volatility 61.33%
  • IV Percentile 20%
  • IV Rank 19.87%
  • IV High 118.81% on 04/08/25
  • IV Low 46.72% on 07/07/25
  • Expected Move (DTE 32) 7.07 (11.08%)
  • Put/Call Vol Ratio 0.66
  • Today's Volume 12,161
  • Volume Avg (30-Day) 4,450
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 55,824
  • Open Int (30-Day) 44,197
  • Expected Range 56.77 to 70.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.82
  • Number of Estimates 6
  • High Estimate 1.63
  • Low Estimate 0.09
  • Prior Year -1.39
  • Growth Rate Est. (year over year) +158.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.62 +5.31%
on 01/05/26
76.76 -16.83%
on 01/06/26
-0.82 (-1.27%)
since 12/16/25
3-Month
36.57 +74.57%
on 10/17/25
76.76 -16.83%
on 01/06/26
+24.87 (+63.82%)
since 10/16/25
52-Week
9.57 +567.08%
on 04/07/25
76.76 -16.83%
on 01/06/26
+44.82 (+235.65%)
since 01/16/25

Most Recent Stories

More News
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

- REDEMPLO is being launched in China by Sanofi - NMPA approval triggers $10 million milestone payment to be paid by Sanofi to Arrowhead subsidiary Visirna Therapeutics

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

– REDEMPLO is the first and only Health Canada-approved siRNA medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS – People living with FCS have extremely...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ARO-INHBE and ARO-ALK7...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, the Company’s Board of Directors approved “inducement”...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain-barrier - Study initiation...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an...

ARWR : 63.84 (-3.64%)
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 37th Annual Healthcare Conference...

ARWR : 63.84 (-3.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 68.86
2nd Resistance Point 67.80
1st Resistance Point 65.82
Last Price 63.84
1st Support Level 62.78
2nd Support Level 61.71
3rd Support Level 59.73

See More

52-Week High 76.76
Last Price 63.84
Fibonacci 61.8% 51.09
Fibonacci 50% 43.17
Fibonacci 38.2% 35.24
52-Week Low 9.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar